As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

Core Viewpoint - Novo Nordisk's shares experienced a significant decline following a disappointing outlook for 2026, primarily due to the impact of the "Most Favored Nations" agreement in the U.S. which is expected to lower prices for its weight-loss drugs [1] Financial Performance - The company anticipates a deceleration in both top- and bottom-line growth for the current year, contradicting earlier expectations of robust performance [1][5] - Despite having launched Wegovy ahead of Eli Lilly, the forecast indicates that growth in volume will not compensate for the decline in prices, leading to a less favorable investment outlook [4][5] Market Position and Competition - Novo Nordisk is preparing for the introduction of generic competition as its key product, semaglutide, is set to lose exclusivity in major markets such as China, Brazil, and Canada [7] - The current valuation of Novo Nordisk is considered stretched, with forward earnings exceeding 18 times, which diminishes the incentive for investors to hold onto the stock [5] Technical Analysis - The stock has fallen below critical moving averages (50-day, 100-day, 200-day), indicating bearish control and sustained downward pressure [6] - Options traders are predicting a further decline in the stock price, estimating it could drop to around $43 by mid-April [7] Analyst Sentiment - Despite the negative outlook and technical indicators, Wall Street analysts maintain a consensus rating of "Moderate Buy" for Novo Nordisk, suggesting some level of confidence in the company's long-term prospects [9]